Department of Surgery, Karditsa General Hospital, Karditsa, Greece.
APMIS. 2010 Feb;118(2):115-24. doi: 10.1111/j.1600-0463.2009.02569.x.
Nitric oxide synthases (NOS) are expressed in colorectal cancer. The aim of this study was to examine the inducible NOS (iNOS) expression in colorectal cancer and to investigate its prognostic relevance. Tissue sections of primary tumors from 132 patients undergoing curative resection for colorectal cancer were immunohistochemically examined for iNOS expression. The expression pattern of iNOS was correlated with various clinicopathological characteristics and survival. iNOS immunoreactivity was observed in the cytoplasm of tumor epithelial cells in 60 patients (45.5%) and positively correlated with lymph node involvement (p = 0.019). No significant correlation was found between iNOS expression and various clinicopathological characteristics, including age, gender, tumor location, tumor size, tumor grade, T stage, and Union International Contra la Cancrum (UICC) stage. Survival analysis showed a significant correlation between iNOS-positive tumors and poor disease-specific survival (p < 0.0001), with independent prognostic significance in multivariate analysis (HR = 4.42; p < 0.0001). Patients with stage II disease and iNOS-positive tumors had significantly worse disease-specific survival than those with iNOS-negative tumors (p < 0.0001). In addition, patients with stage III disease and iNOS-positive tumors had significantly worse disease-specific survival than those with iNOS-negative tumors (p = 0.001). The ability of iNOS to predict outcome in colorectal cancer patients may be independent of other known prognostic factors, providing a new molecular marker with significant potential for clinical utility.
诱导型一氧化氮合酶(iNOS)在结直肠癌中表达。本研究旨在检测结直肠癌中诱导型一氧化氮合酶(iNOS)的表达,并探讨其与预后的相关性。对 132 例接受结直肠癌根治性切除术的患者的原发肿瘤组织切片进行免疫组织化学检查,以检测 iNOS 的表达。iNOS 的表达模式与各种临床病理特征和生存相关。在 60 例患者(45.5%)的肿瘤上皮细胞胞质中观察到 iNOS 免疫反应性,与淋巴结受累呈正相关(p = 0.019)。iNOS 表达与年龄、性别、肿瘤部位、肿瘤大小、肿瘤分级、T 分期和国际抗癌联盟(UICC)分期等各种临床病理特征之间无显著相关性。生存分析显示,iNOS 阳性肿瘤与疾病特异性生存不良显著相关(p < 0.0001),在多因素分析中具有独立的预后意义(HR = 4.42;p < 0.0001)。II 期疾病且 iNOS 阳性肿瘤患者的疾病特异性生存率明显低于 iNOS 阴性肿瘤患者(p < 0.0001)。此外,III 期疾病且 iNOS 阳性肿瘤患者的疾病特异性生存率明显低于 iNOS 阴性肿瘤患者(p = 0.001)。iNOS 预测结直肠癌患者预后的能力可能独立于其他已知的预后因素,为临床应用提供了一种具有显著潜力的新的分子标志物。